- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01494038
Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence Settings
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
TB disease is the most common HIV-related opportunistic infection and is a leading cause of death among HIV-infected persons in low-income settings. When TB occurs during or soon after pregnancy, it can cause complications for the mother as well as infant TB or death. Infant TB is very difficult to diagnose, and up to half of infant TB cases are caused by maternal TB. It has been shown that treatment for active TB is safe and effective during pregnancy and that IPT is safe and effective in preventing TB infection in HIV-infected adults. However, the safety of IPT in HIV-infected pregnant women is not known, especially in regard to its combination with highly active retroviral therapy (HAART). This study evaluated the safety of immediate (antepartum, or before delivery) versus deferred (postpartum, or after delivery) IPT among HIV-infected pregnant women in high TB incidence settings.
HIV-infected pregnant women were randomly assigned (1:1) to one of two arms: Arm A (immediate/antepartum INH) and Arm B (deferred/postpartum INH group). Women in both arms received oral prenatal multivitamins and pyridoxine (vitamin B6) once daily from study entry through Week 40 postpartum.
Study visits for women occurred at screening, entry, every 4 weeks until labor and delivery, at labor and delivery, and every 4 weeks after delivery until 48 weeks postpartum. Visits consisted of giving a medical history and undergoing a physical exam and blood collection; all visits through the delivery visit also included an obstetrical exam. Presence of HIV infection was documented at screening and a tuberculin skin test (TST) was administered at the delivery visit and at the Week 44 postpartum visit. Study visits for infants occurred at birth and at several time points through Week 48. These visits included a medical history, physical exam, and blood collection. Intensive pharmacokinetic (PK) samples, that is, samples taken at many different time points within a 24-hour test period, were collected from a small subset of women, one test period at antepartum and one at postpartum. Sparse PK samples, that is, samples taken at fewer time points within the test period, were collected on all women, once each at antepartum and postpartum.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Gaborone, Botswana
- Gaborone CRS
-
Gaborone, Botswana
- Molepolole CRS
-
-
-
-
-
Port-au-Prince, Haiti, HT-6110
- Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
-
-
-
-
Maharashtra
-
Pune, Maharashtra, India, 411001
- Byramjee Jeejeebhoy Medical College (BJMC) CRS
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 1862
- Soweto IMPAACT CRS
-
-
Western Cape Province
-
Cape Town, Western Cape Province, South Africa, 7505
- Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS
-
Cape Town, Western Cape Province, South Africa, 7505
- Fam-Cru Crs
-
-
-
-
-
Moshi, Tanzania
- Kilimanjaro Christian Medical Centre (KCMC)
-
-
-
-
-
Chiang Mai, Thailand, 50200
- Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
-
-
-
-
-
Kampala, Uganda
- MU-JHU Research Collaboration (MUJHU CARE LTD) CRS
-
-
-
-
-
Chitungwiza, Zimbabwe
- St Mary's CRS
-
Chitungwiza, Zimbabwe
- Seke North CRS
-
Harare, Zimbabwe
- Harare Family Care CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented HIV-1 infection, defined as positive results from two samples collected at different time points. All samples tested must be whole blood, serum, or plasma. More information on this criterion can be found in the protocol.
- Documented HIV treatment, according to World Health Organization (WHO) guidelines, for prevention of mother-to-child transmission (PMTCT) and standard of care for HIV infection
- Pregnant females age 18 years or older
- Pregnant females between greater than or equal to 13 and less than 18 who are able and willing to provide signed informed consent under local law or pregnant females unable to consent under local law whose parents/legal guardians provide consent or "minimum age of consent according to locally applicable laws or regulations"
- Pregnancy gestational age confirmed by best available method at site to be greater than or equal to 14 weeks through less than or equal to 34 weeks (34 weeks, 6 days)
- Weight greater than or equal to 35 kg at screening
The following laboratory values obtained within 30 days prior to study entry:
- Absolute neutrophil count (ANC) greater than or equal to 750 cells/mm^3
- Hemoglobin greater than or equal to 7.5 g/dL
- Platelet count greater than or equal to 50,000/mm^3
- Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alkaline phosphatase (ALT)/serum glutamic pyruvic transaminase (SGPT), and total bilirubin less than or equal to 1.25 times the upper limit of normal (ULN). (Note: If participant is taking atazanavir, direct bilirubin may be used to determine eligibility.)
- Intent to remain in current geographical area of residence for the duration of the study
Exclusion Criteria:
- Any woman with a positive TB symptom screen per WHO guidelines, including any one or more of the following: any cough, fever, self-reported weight loss, or night sweats. Note: If a potential participant is found to be negative for TB upon further testing, the participant may be rescreened for the study.
- Any positive acid-fast bacillus (AFB) smear, Xpert, or any other rapid TB screening test or culture from any site within the past 12 weeks, or chest radiograph (x-ray) with findings suggestive of active TB, or clinician suspects active TB
- Known exposure to AFB smear-positive active TB case within past 12 weeks prior to study entry
- Reported INH exposure (more than 30 days) in the past year prior to study entry
- Receipt of any TB or atypical mycobacteria therapy for more than 30 days in the past year
- Evidence of acute hepatitis, such as jaundice, dark urine (not concentrated urine), and/or acholic stools sustained for more than 3 days within 90 days prior to entry. More information on this criterion can be found in the protocol.
- Grade 1 or higher peripheral neuropathy. More information on this criterion can be found in the protocol.
- History of acute systemic adverse reaction or allergy to INH
- Known current heavy alcohol use (more than 2 drinks per week) or alcohol exposure that, in the investigator's opinion, would compromise participation and the outcome of this study
- Presence of new AIDS-defining opportunistic infection that has been treated less than 30 days prior to study entry
- Receipt of an investigational agent or chemotherapy for active malignancy within 30 days prior to study entry
- Any clinically significant diseases (other than HIV infection) or clinically significant findings during the screening medical history or physical examination that, in the investigator's opinion, would compromise participation and the outcome of this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (Immediate INH Treatment)
Women in Arm A received immediate, or antepartum-initiated, INH treatment.
Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
|
300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
|
Experimental: Arm B (Deferred INH Treatment)
Women in Arm B received deferred, or postpartum-initiated, INH treatment.
Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
|
300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence Rate of Combined Endpoint: Grade 3 or Higher Adverse Events (AEs) Related to Treatment, or AE Causing Discontinuation of Treatment
Time Frame: Measured from study entry through Week 48 after birth
|
Incidence rate, calculated by Mantel-Haenszel (MH), weighted by gestational age strata 1) gestational age at entry less than 24 weeks or 2) gestational age at entry greater than or equal to 24 weeks.
AE's include laboratory results, signs/symptoms, or diagnoses; graded as per Division of AIDS (DAIDS) or by protocol-defined hepatotoxicity measures.
Related to treatment indicates possibly, probably, or definitely related to INH or Placebo for INH as judged by Independent Endpoint Review Committee.
Discontinuation refers to permanent discontinuation of study treatment.
|
Measured from study entry through Week 48 after birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Mothers With a Fetal Death
Time Frame: Measured from study entry through end of pregnancy
|
Fetal deaths include both stillbirths and spontaneous abortions; in case of a multiple birth, mothers who had at least one fetal death
|
Measured from study entry through end of pregnancy
|
Number of Mothers With a Fetus Small for Gestational Age
Time Frame: Measured at delivery
|
Small for gestational age was determined by physician at site
|
Measured at delivery
|
Number of Mothers With an Infant Born Prematurely
Time Frame: Measured at delivery
|
Premature birth is defined as gestational age of < 37 weeks at delivery.
|
Measured at delivery
|
Number of Mothers With a Low Birth-weight Infant
Time Frame: Measured on day of birth
|
Low birth weight is defined as weight < 2500 mg
|
Measured on day of birth
|
Number of Mothers With an Infant With a Congenital Anomaly
Time Frame: Measured from study entry through Week 48 after birth
|
Includes congenital anomalies meeting the Metropolitan Atlanta Congenital Defects Program criteria.
|
Measured from study entry through Week 48 after birth
|
Number of Mothers With an Adverse Pregnancy Outcome: Spontaneous Abortion, Stillbirth, Premature Birth, Low Birth Weight, or Congenital Anomaly
Time Frame: Measured from study entry through Week 48 after birth
|
In case of a multiple birth, mothers who had at least one adverse pregnancy outcome.
Spontaneous abortion is intra-uterine fetal death prior to 20 weeks of gestational age; stillbirth, the same, >= 20 weeks; preterm delivery, < 37 weeks of gestational age; low birth weight, < 2,500 grams, and congenital anomalies meeting the Metropolitan Atlanta Congenital Defects Program criteria.
|
Measured from study entry through Week 48 after birth
|
Number of Infants With Grade 3 or Higher Clinical or Laboratory AE
Time Frame: Measured from study entry through Week 48 after birth
|
Laboratory, sign/symptom, or diagnoses graded as 3 or higher by DAIDS criteria.
|
Measured from study entry through Week 48 after birth
|
Number of Infants With Grade 3 or Higher Clinical or Laboratory AE Related to Treatment
Time Frame: Measured from study entry through Week 48 after birth
|
As before, but AE is judged to be possibly, probably, or definitely related to INH or Placebo for INH, by clinic medical staff
|
Measured from study entry through Week 48 after birth
|
Number of Infants Which Are HIV-infected
Time Frame: Measured from study entry through study Week 44
|
HIV infection determined during follow-up period.
Infection at birth or during breastfeeding
|
Measured from study entry through study Week 44
|
Number of Infants Hospitalized
Time Frame: Measured from study entry through Week 48 after birth
|
Hospitalization due to reasons other than birth
|
Measured from study entry through Week 48 after birth
|
Incidence Rate of TB Infection Among Mothers
Time Frame: Measured from study entry to Week 48 after birth
|
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.
Probable or confirmed TB infection, as judged by Secondary Endpoint Review Committee
|
Measured from study entry to Week 48 after birth
|
Incidence Rate of Tuberculosis (TB) Among Infants
Time Frame: Measured from study entry through Week 48 after birth
|
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.
Probable or confirmed TB, or congenital TB as defined using the Cantwell criteria (see reference), judged by the Secondary Endpoint Review Committee.
Includes an infant death due to unknown cause.
|
Measured from study entry through Week 48 after birth
|
Incidence Rate of Infant Death
Time Frame: Measured from study entry through Week 48 after birth
|
Incidence rate was calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through Week 48 after birth
|
Incidence Rate of Maternal Deaths
Time Frame: Measured from study entry through Week 48 postpartum
|
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through Week 48 postpartum
|
Incidence Rate of Combined Endpoints: Maternal TB or Maternal Death
Time Frame: Measured from study entry through Week 48 after birth
|
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through Week 48 after birth
|
Incidence Rate of Combined Endpoints: Infant TB or Infant Death
Time Frame: Measured from study entry through Week 48 after birth
|
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through Week 48 after birth
|
Incidence Rate of Combined Endpoints: Maternal TB, Maternal Death, Infant TB, or Infant Death
Time Frame: Measured from study entry through Week 48 after birth
|
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through Week 48 after birth
|
Incidence Rate of Combined Endpoint, Antepartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE
Time Frame: Measured from study entry through end of pregnancy
|
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata
|
Measured from study entry through end of pregnancy
|
Incidence Rate of Combined Endpoint, up to 12 Weeks Postpartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE
Time Frame: Measured from study entry through 12 weeks after birth
|
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through 12 weeks after birth
|
Incidence Rate, Antepartum, of Grade 3 or Higher AE
Time Frame: Measured from study entry through end of pregnancy
|
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through end of pregnancy
|
Incidence Rate, up to 12 Weeks Postpartum, of Grade 3 or Higher AE
Time Frame: Measured from study entry through 12 weeks postpartum
|
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through 12 weeks postpartum
|
Incidence Rate, Antepartum, of Hepatotoxicity, Defined by Protocol-specific Definition of Hepatotoxicity, Related to Treatment
Time Frame: Measured from study entry through delivery
|
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.
Protocol-specific definition of hepatotoxicity: Any one of the following: 1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times the upper limit of normal (ULN), where ULN is specified by the clinic physician; 2) Total bilirubin > 3 X ULN; 3) ALT greater than 3 X ULN and total bilirubin greater than 2 X ULN; or 4) ALT > 3 X ULN and persistent symptomatic clinical hepatitis
|
Measured from study entry through delivery
|
Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Related to Treatment
Time Frame: Measured from study entry through 12 weeks postpartum
|
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata
|
Measured from study entry through 12 weeks postpartum
|
Incidence Rate, Antepartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause
Time Frame: Measured from study entry through delivery
|
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through delivery
|
Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause
Time Frame: Measured from study entry through 12 weeks postpartum
|
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through 12 weeks postpartum
|
Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment
Time Frame: Measured from study entry through delivery
|
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.
Hepatotoxicity definition as defined by DAIDS AE grading criteria 1.0.
|
Measured from study entry through delivery
|
Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment
Time Frame: Measured from study start through 12 weeks postpartum
|
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata
|
Measured from study start through 12 weeks postpartum
|
Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Any Cause
Time Frame: Measured from study entry through delivery
|
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study entry through delivery
|
Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Any Cause
Time Frame: Measured from study start through 12 weeks postpartum
|
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.
|
Measured from study start through 12 weeks postpartum
|
Number of Mothers With Tuberculosis Resistant to INH
Time Frame: Measured from study entry through Week 48 postpartum
|
Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of mothers who develop culture-confirmed TB
|
Measured from study entry through Week 48 postpartum
|
Number of Infants With Tuberculosis Resistant to INH
Time Frame: Measured from study entry through Week 48 after birth
|
Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of infants who develop culture-confirmed TB
|
Measured from study entry through Week 48 after birth
|
Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve of Plasma Concentration Versus Time (AUC24h), for INH
Time Frame: Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
|
Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data.
AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program.
A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used,
|
Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
|
Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve (AUC24h), for EFV
Time Frame: Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
|
Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data.
AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program.
A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used,
|
Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
|
Agreement Between Interferon-gamma Release Assay (IGRA) TB Test and Tuberculin Skin Test (TST) Results, Women at Delivery
Time Frame: Measured at delivery
|
IGRA done by Quantiferon Gold Test (QGIT).
For women, TST is considered positive if greater than or equal to 5 mm
|
Measured at delivery
|
Agreement Between IGRA and TST TB Test Results, Infant
Time Frame: Measured at week 44 after birth
|
The TST result was positive if greater than or equal to 10 mm in HIV-negative infants, or greater than or equal to 5 mm in HIV-positive infants.
|
Measured at week 44 after birth
|
Agreement Between IGRA and TST TB Tests, Women at 44 Weeks Postpartum
Time Frame: Measured at Week 44 postpartum
|
IGRA done by Quantiferon Gold Test (QGIT).
For women, TST is considered positive if greater than or equal to 5 mm
|
Measured at Week 44 postpartum
|
Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Self-report
Time Frame: Adherence reported every 4 weeks during active treatment; study entry through week 28 for Arm A, week 12 postpartum through week 40 postpartum for Arm B
|
Adherence is the percentage of expected doses taken during the 28 week active treatment period, categorized as poor (<60%), reasonable (>= 60%, <80%), good (>=80%, <90%), or excellent (>= 90%).
Measured by participant's self-report of doses taken within the last 3 days.
|
Adherence reported every 4 weeks during active treatment; study entry through week 28 for Arm A, week 12 postpartum through week 40 postpartum for Arm B
|
Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Pill Count
Time Frame: Adherence reported every 4 weeks during active treatment; study entry through week 28 for Arm A, week 12 postpartum through week 40 postpartum for Arm B
|
Adherence is the percentage of expected doses taken during the 28 week active treatment period.
Pill count: participants returned their prescription pill containers, and the remaining (unused) pills were counted.
|
Adherence reported every 4 weeks during active treatment; study entry through week 28 for Arm A, week 12 postpartum through week 40 postpartum for Arm B
|
Collaborators and Investigators
Investigators
- Study Chair: Amita Gupta, MD, MHS, Johns Hopkins University
Publications and helpful links
General Publications
- Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD000171. doi: 10.1002/14651858.CD000171.pub3.
- Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007 Jan 20;334(7585):136. doi: 10.1136/bmj.39000.486400.55. Epub 2006 Nov 3.
- Cantwell MF, Snider DE Jr, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA. 1994 Aug 17;272(7):535-9.
- Montepiedra G, Kim S, Weinberg A, Theron G, Sterling TR, LaCourse SM, Bradford S, Chakhtoura N, Jean-Philippe P, Evans S, Gupta A. Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. Clin Infect Dis. 2021 Aug 2;73(3):e587-e593. doi: 10.1093/cid/ciaa1674.
- Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A; IMPAACT P1078 TB APPRISE Study Team. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med. 2019 Oct 3;381(14):1333-1346. doi: 10.1056/NEJMoa1813060.
Helpful Links
- Manual for Expedited Reporting of Adverse Events to Division of AIDS (DAIDS), Version 2.0, January 2010
- Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 (Clarification, August 2009)
- Metropolitan Atlanta Congenital Defects Program (MACDP)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- Antitubercular Agents
- Fatty Acid Synthesis Inhibitors
- Isoniazid
Other Study ID Numbers
- P1078
- 10732 (Registry Identifier: DAIDS ES)
- IMPAACT P1078
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Isoniazid (INH)
-
Huashan HospitalCompletedTuberculosis | SilicosisChina
-
Centers for Disease Control and PreventionVA Office of Research and DevelopmentCompletedTuberculosisUnited States, Canada, Spain, Brazil
-
Orient Pharma Co., Ltd.National Defense Medical Center, Taiwan; National Research Program for Biopharmaceuticals...Completed
-
Makerere UniversityRecruiting
-
Centers for Disease Control and PreventionKenya Medical Research InstituteCompletedTuberculosis | Drug-resistant Tuberculosis | Isoniazid Resistant Tuberculosis (Disorder)India
-
National Taiwan University HospitalCompleted
-
Dr. Nyanda Elias NtinginyaKing's College London; Makerere University; Stichting Katholieke Universiteit-... and other collaboratorsRecruitingDiabetes Mellitus | TuberculosisUganda, Tanzania
-
University of WashingtonThrasher Research FundCompleted
-
Huashan HospitalWenling No.1 People's Hospital, ChinaUnknownSilicosis TuberculosisChina
-
Beijing Children's HospitalUnknown